Quintet Private Bank (Europe)’s Apellis Pharmaceuticals APLS Stock Holding History

Quintet Private Bank (Europe)’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-452	Closed	-$7.82K	–	196
2025 Q2	$7.82K	Hold	452	–	–	﹤0.01%	195
2025 Q1	$9.88K	Sell	452 -300	-40%	-$8.29K	﹤0.01%	177
2024 Q4	$24K	Hold	752	–	–	﹤0.01%	168
2024 Q3	$21.7K	Buy	752 +61	+9%	+$2.26K	﹤0.01%	161
2024 Q2	$28.9K	Buy	691 +53	+8%	+$2.4K	﹤0.01%	163
2024 Q1	$44K	Sell	638 -114	-15%	-$7.27K	﹤0.01%	178
2023 Q4	$45K	Hold	752	–	–	﹤0.01%	154
2023 Q3	$28.6K	Sell	752 -13	-2%	-$571	﹤0.01%	178
2023 Q2	$68.2K	Buy	765 +613	+403%	+$52.9K	﹤0.01%	184
2023 Q1	$10K	Buy	+152	New	+$8.77K	﹤0.01%	240
2022 Q2	$68.2K	Buy	+765	New	+$34.9K	﹤0.01%	184

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Quintet Private Bank (Europe)'s APLS Position: Q3 2025 in Review

Quintet Private Bank (Europe) sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 452 shares — an estimated $7.82K sold.

Quintet Private Bank (Europe) first reported a position in APLS in Q2 2022 and held it in 11 quarters. The position peaked at $68.2K in Q2 2023. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

Quintet Private Bank (Europe) reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Quintet Private Bank (Europe) sold 452 Apellis Pharmaceuticals shares in Q3 2025, an estimated $7.82K.
Quintet Private Bank (Europe) first reported a position in Apellis Pharmaceuticals in Q2 2022 and held it in 11 quarters.
Quintet Private Bank (Europe)'s Apellis Pharmaceuticals position peaked at $68.2K in Q2 2023.
273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Quintet Private Bank (Europe)'s 13F filing for Q3 2025, filed 7 Oct 2025.